CUSIP: 36870A108
Q1 2017 13F Holders as of 31 Mar 2017
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
2,943,597
-
Share change
-
+1,600,202
-
Total reported value
-
$30,908,000
-
Price per share
-
$10.50
-
Number of holders
-
16
-
Value change
-
+$16,983,859
-
Number of buys
-
15
-
Number of sells
-
5
Quarterly Holders Quick Answers
What is CUSIP 36870A108?
CUSIP 36870A108 identifies GEMP - GEMPHIRE THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2017
-
Previous quarter:
Q4 2016
Recent filing periods for CUSIP 36870A108:
Institutional Holders of GEMPHIRE THERAPEUTICS INC - COM (GEMP) as of Q1 2017
As of 31 Mar 2017,
GEMPHIRE THERAPEUTICS INC - COM (GEMP) was held by
16 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,943,597 shares.
The largest 10 holders included
Cormorant Asset Management, LLC, Exchange Capital Management, Inc., ADAGE CAPITAL PARTNERS GP, L.L.C., HIGHLAND CAPITAL MANAGEMENT LP, Cambridge Investment Research Advisors, Inc., DAFNA Capital Management LLC, RENAISSANCE TECHNOLOGIES LLC, VANGUARD GROUP INC, SEGALL BRYANT & HAMILL, LLC, and DEUTSCHE BANK AG\.
This page lists
16
institutional shareholders reporting positions in this security
for the Q1 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.